TG Therapeutics Presents New BRIUMVI Data at 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics presented new data on BRIUMVI for relapsing multiple sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting, highlighting findings on immunoglobulin levels, infusion tolerability, and safety from key studies. The company has made all presentation materials available on its website. BRIUMVI is a novel monoclonal antibody approved by the FDA for RMS, targeting CD20-expressing B-cells. TG Therapeutics remains committed to providing ongoing updates and insights related to BRIUMVI.

TG Therapeutics, Inc. (NASDAQ: TGTX) recently presented new data on BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The company highlighted findings from key studies on immunoglobulin levels, infusion tolerability, and safety, with all presentation materials now available on their website [1].

BRIUMVI is a novel monoclonal antibody approved by the FDA for the treatment of RMS, targeting CD20-expressing B-cells. The drug is uniquely designed to lack certain sugar molecules, a process known as glycoengineering, which allows for efficient B-cell depletion at low doses. The company's presentations focused on the following key areas:

1. No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections: A presentation by Dr. Bruce Cree from the Weill Institute for Neurosciences, University of California, San Francisco, discussed the lack of association between decreases in serum immunoglobulin levels and serious infections in patients treated with BRIUMVI. This finding is significant as it suggests that the drug may not increase the risk of infections despite its B-cell depleting mechanism [2].

2. Retrospective Evaluation of Infusion Tolerability: Dr. Edward Fox, National Physician Liaison and VP, MS Global Operations at TG Therapeutics, presented data from the ENAMOR survey, which retrospectively evaluated the infusion tolerability of BRIUMVI. The study found that the drug was well-tolerated in real-world settings, with infusion reactions being manageable through premedication and other supportive measures [3].

3. Safety and Tolerability of 30-Minute Ublituximab Infusions: Dr. John Foley from Rocky Mountain Multiple Sclerosis, Salt Lake City, Utah, presented updates from the ENHANCE study, which assessed the safety and tolerability of 30-minute BRIUMVI infusions. The study found that shorter infusion times did not compromise the drug's efficacy or increase the risk of infusion reactions [4].

TG Therapeutics remains committed to providing ongoing updates and insights related to BRIUMVI, with the company's presentations and data from the ULTIMATE I & II trials available on their website [1]. The ULTIMATE I & II trials are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, enrolling a total of 1,094 patients with RMS across 10 countries. The trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University [5].

References:
[1] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-data-presentations-briumvi-multiple-1
[2] Weill Institute for Neurosciences, University of California, San Francisco, CA
[3] Dr. Edward Fox – TG Therapeutics - National Physician Liaison – VP, MS Global Operations
[4] Dr. John Foley – Rocky Mountain Multiple Sclerosis, Salt Lake City, Utah
[5] ClinicalTrials.gov (NCT03277261; NCT03277248)